1. Home
  2. KEQU vs CHRS Comparison

KEQU vs CHRS Comparison

Compare KEQU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KEQU
  • CHRS
  • Stock Information
  • Founded
  • KEQU 1906
  • CHRS 2010
  • Country
  • KEQU United States
  • CHRS United States
  • Employees
  • KEQU N/A
  • CHRS 235
  • Industry
  • KEQU Medical Specialities
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KEQU Industrials
  • CHRS Health Care
  • Exchange
  • KEQU Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • KEQU 183.3M
  • CHRS 134.4M
  • IPO Year
  • KEQU N/A
  • CHRS 2014
  • Fundamental
  • Price
  • KEQU $65.19
  • CHRS $1.22
  • Analyst Decision
  • KEQU
  • CHRS Strong Buy
  • Analyst Count
  • KEQU 0
  • CHRS 4
  • Target Price
  • KEQU N/A
  • CHRS $5.38
  • AVG Volume (30 Days)
  • KEQU 21.6K
  • CHRS 2.4M
  • Earning Date
  • KEQU 03-05-2025
  • CHRS 03-12-2025
  • Dividend Yield
  • KEQU N/A
  • CHRS N/A
  • EPS Growth
  • KEQU 168.79
  • CHRS N/A
  • EPS
  • KEQU 6.31
  • CHRS N/A
  • Revenue
  • KEQU $199,637,000.00
  • CHRS $304,340,000.00
  • Revenue This Year
  • KEQU N/A
  • CHRS $2.47
  • Revenue Next Year
  • KEQU N/A
  • CHRS N/A
  • P/E Ratio
  • KEQU $9.84
  • CHRS N/A
  • Revenue Growth
  • KEQU N/A
  • CHRS 44.19
  • 52 Week Low
  • KEQU $27.00
  • CHRS $0.66
  • 52 Week High
  • KEQU $67.20
  • CHRS $2.87
  • Technical
  • Relative Strength Index (RSI)
  • KEQU 57.72
  • CHRS 44.03
  • Support Level
  • KEQU $57.58
  • CHRS $1.03
  • Resistance Level
  • KEQU $65.00
  • CHRS $1.23
  • Average True Range (ATR)
  • KEQU 2.48
  • CHRS 0.13
  • MACD
  • KEQU -0.25
  • CHRS -0.02
  • Stochastic Oscillator
  • KEQU 68.59
  • CHRS 38.89

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Share on Social Networks: